Figure 5

(a) Time course of systolic blood pressure (SBP) and heart rate (HR) in groups that received either intracerebroventricular (ICV) RNH-6270 (100 μg day−1) or vehicle. (b) In vivo electron spin resonance signal decay rates before and after treatment in the ICV-vehicle and ICV-RNH-6270 groups. *P<0.05, #P<0.001. (c) Urinary norepinephrine (NE) excretion levels before and after treatment in the ICV-RNH-6270 group.